Lyell Immunopharma, Inc.

Nasdaq:LYEL

Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA

Financials

18 shown

Type	Period	Ended	Filed
10-Q	Q3 2025	9/30/25	11/12/25	→
10-Q	Q2 2025	6/30/25	8/12/25	→
10-Q	Q1 2025	3/31/25	5/13/25	→
10-K	FY 2024	12/31/24	3/11/25	→
10-Q	Q3 2024	9/30/24	11/7/24	→
10-Q	Q2 2024	6/30/24	8/7/24	→
↓

Earnings Releases (8-K)

18 shown

Filed	Period
11/12/25	Q4 FY2025	→
8/12/25	Q3 FY2025	→
5/13/25	Q2 FY2025	→
3/11/25	Q1 FY2025	→
11/7/24	Q4 FY2024	→
8/7/24	Q3 FY2024	→
↓

News (8-K)

35 shown

Filed	Type	Description
3/9/26	Exec Change	Departure or Appointment of Directors or Certain Officers	→
12/8/25	Other	Other Events	→
12/5/25	Other	Amendments to Articles of Incorporation or Bylaws	→
11/10/25	Agreement	Entry into a Material Definitive Agreement	→
11/3/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
9/16/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
↓

Prospectuses & Registrations

21 shown

Filed	Form	Description
12/18/25	424B5	424B5	→
12/5/25	S-3	S-3	→
8/12/25	S-3	S-3	→
7/31/25	424B5	424B5	→
7/18/25	S-3	S-3	→
4/21/25	ARS	ARS	→
↓

Filing History(295 filings)

TypeDateAccessionPeriodSize

Mar 9, 2026

0001012975-26-000235STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Mar 6, 2026

16.0 KB

Mar 9, 2026

0001012975-26-000234STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Mar 6, 2026

20.9 KB

8-K

Mar 9, 2026

0001193125-26-0976158-K

Mar 6, 2026

196.1 KB

Feb 12, 2026

0001327111-26-000002

Feb 11, 2026

5.1 KB

Feb 12, 2026

0001866154-26-000002

Feb 11, 2026

5.1 KB

Feb 12, 2026

0001907345-26-000002

Feb 11, 2026

5.1 KB

Feb 11, 2026

0001866154-26-000001

Feb 9, 2026

9.5 KB

Feb 11, 2026

0001907345-26-000001

Feb 9, 2026

9.4 KB

Feb 11, 2026

0001327111-26-000001

Feb 9, 2026

9.2 KB

Feb 11, 2026

0001771329-26-000001

Feb 10, 2026

5.8 KB

Feb 11, 2026

0002095702-26-000002

Feb 10, 2026

6.6 KB

Feb 11, 2026

0001959742-26-000001

Feb 10, 2026

6.5 KB

Jan 6, 2026

0002095702-26-000001

Dec 24, 2025

6.4 KB

424B5

Dec 18, 2025

0001193125-25-324801424B5

—

237.6 KB

EFFECT

Dec 15, 2025

9999999995-25-003741

—

1.7 KB

8-K

Dec 8, 2025

0001193125-25-3104698-K

Dec 7, 2025

142.0 KB

S-3

Dec 5, 2025

0001193125-25-309779S-3

—

568.3 KB

8-K

Dec 5, 2025

0001193125-25-3096218-K

Dec 3, 2025

364.7 KB

SCHEDULE 13G/A

Nov 14, 2025

0001012975-25-000768

—

64.1 KB

SCHEDULE 13G/A

Nov 14, 2025

0001104659-25-112479

—

22.3 KB

SCHEDULE 13G

Nov 13, 2025

0001140361-25-042006

—

6.6 KB

Nov 12, 2025

0001327111-25-000007

Nov 10, 2025

4.6 KB

Nov 12, 2025

0002095702-25-000003

Nov 10, 2025

5.1 KB

Nov 12, 2025

0001907345-25-000006

Nov 10, 2025

4.6 KB

Nov 12, 2025

0001866154-25-000006

Nov 10, 2025

4.7 KB

25 filings shown

Filed	Form	Description
4/21/25	DEF 14A	DEF 14A	→
4/10/25	PRE 14A	PRE 14A	→
4/22/24	DEFA14A	DEFA14A	→
4/22/24	DEF 14A	DEF 14A	→
4/27/23	DEFA14A	FORM DEFA14A	→
4/27/23	DEF 14A	DEF 14A	→
↓

Lyell Immunopharma, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(295 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
3/9/26	4	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	→
3/9/26	4	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	→
2/12/26	4	4	→
2/12/26	4	4	→
2/12/26	4	4	→
2/11/26	4	4	→
↓

Filed	Form	Description
12/15/25	EFFECT	EFFECT	→
11/14/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
11/14/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
11/13/25	SCHEDULE 13G	SCHEDULE 13G	→
11/12/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
8/19/25	SCHEDULE 13G	SCHEDULE 13G	→
↓